az3

AZ31 is an ATM inhibitor with potency, high selectivity, and oral activity.AZ31 inhibits ATM enzymes, intracellular ATM, with IC50 values of <1.2 nM and 46 nM, respectively.AZ31 exhibits excellent ATR selectivity, PIKK family selectivity, and pan-kinase selectivity.AZ31 is a potent in vitro radiosensitizer that can be used for cancer research.

AZ32 is an orally bioavailable, blood-brain barrier-penetrating ATM inhibitor with an IC50 of <6.2 nM for the ATM enzyme and an IC50 of 0.31 μM for ATM in cells.

AZ3976 is an inhibitor of PAI-1 with an IC50 of 16 μM in a plasma clot lysis assay. AZ3976 displays profibrinolytic activities.

AZ3246 is an orally active, selective inhibitor of HPK1 with an IC50 of less than 3 nM. It induces IL-2 secretion in T cells with an EC50 of 90 nM. AZ3246 also functions as a low-volume, low-clearance antitumor compound.

AZ3146 is a selective Mps1 inhibitor with IC50 of ~35 nM.

AZ304 is an ATP-competitive dual BRAF kinase inhibitor, effectively inhibiting BRAF (WT), BRAF (V600E), and wild-type CRAF [IC50s: 79 38 68 nM].

AZ3391 is a quinoxaline derivative that is a potent inhibitor of PARP. AZ3391 has potential for the study of diseases and conditions occurring in central nervous system tissues (e.g., brain and spinal cord).

AZ3971 is a potent BACE1 inhibitor. AZ3971 blocks BACE1-mediated cleavage of APP and inhibits Aβ42 production HEK cells overexpressing the APP protein which carries the Swedish mutation (HEK.APPswe).

AZ3451 is an allosteric antagonist of protease-activated receptor-2 (PAR2, IC50: 23 nM).

AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).